Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2022
IDEAYA Biosciences appoints Catherine Mackey to its board
IDEAYA Biosciences announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.
2020
IDEAYA and Pfizer expanded clinical trial collaboration and supply agreement
IDEAYA announced that it had expanded its clinical trial collaboration and supply agreement with Pfizer for an IDEAYA-sponsored combination study of IDE196 and crizotinib. IDEAYA will sponsor the study and Pfizer will supply crizotinib.
2020
IDEAYA-GSK synthetic lethality partnership takes effect
IDEAYA announced that its Collaboration, Option and License Agreement with GSK became effective following HSR clearance; IDEAYA received a $100 million upfront payment.
2020
Glaxo Group closes $20 million IDEAYA equity investment
IDEAYA announced the closing of a private placement in which Glaxo Group purchased 1,333,333 IDEAYA common shares at $15 per share, providing IDEAYA approximately $20 million in proceeds.
2020
IDEAYA announces pricing of public stock offering
IDEAYA announced the pricing of an underwritten public offering of 6,666,667 common shares at $15.00 per share. The offering was expected to close on or about June 22, 2020, subject to customary conditions.
2019
IDEAYA and Foundation Medicine enter genomic profiling collaboration
IDEAYA Biosciences entered into a collaboration with Foundation Medicine to support IDEAYA's tissue-type agnostic strategy, including genomic profiling of tumor samples from its ongoing Phase 1/2 clinical trial and analyses of Foundation Medicine's FoundationCORE database.